Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines
K Chen, L Zhang, Z Fang, J Li, C Li, W Song… - Frontiers in …, 2023 - frontiersin.org
By the end of 2022, different variants of Omicron had rapidly spread worldwide, causing a
significant impact on the Coronavirus disease 2019 (COVID-19) pandemic situation …
significant impact on the Coronavirus disease 2019 (COVID-19) pandemic situation …
The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review
AM Marchese, M Rousculp, J Macbeth… - The Journal of …, 2024 - academic.oup.com
Abstract Coronavirus disease 2019 (COVID-19) continues to be a global health concern,
and booster doses are necessary for maintaining vaccine-mediated protection, limiting the …
and booster doses are necessary for maintaining vaccine-mediated protection, limiting the …
COVID-19 vaccines: where did we stand at the end of 2023?
K Lundstrom - Viruses, 2024 - mdpi.com
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
Immunogenicity and safety of a bivalent (omicron BA. 5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim …
C Bennett, W Woo, M Bloch, K Cheung… - The Lancet Infectious …, 2024 - thelancet.com
Background SARS-CoV-2 variants evade immunity despite vaccination with prototype
COVID-19 vaccines or previous infection. The 2019nCoV-311 (part 2) study is evaluating …
COVID-19 vaccines or previous infection. The 2019nCoV-311 (part 2) study is evaluating …
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition
C Fischer, E Willscher, L Paschold, C Gottschick… - npj Vaccines, 2024 - nature.com
The rapid development of safe and effective vaccines helped to prevent severe disease
courses after SARS-CoV-2 infection and to mitigate the progression of the COVID-19 …
courses after SARS-CoV-2 infection and to mitigate the progression of the COVID-19 …
Progress with COVID vaccine development and implementation
RW Titball, DI Bernstein, NVJ Fanget, RA Hall… - npj Vaccines, 2024 - nature.com
Check for updates January 2024 marks the fourth anniver-sary of the identification of SARS-
CoV-2 as the causative agent of the COVID-19 epidemic. Since that time, vaccine …
CoV-2 as the causative agent of the COVID-19 epidemic. Since that time, vaccine …
[HTML][HTML] Mechanisms and implications of IgG4 responses to SARS-CoV-2 and other repeatedly administered vaccines
AM Marchese, L Fries, H Beyhaghi, M Vadivale, M Zhu… - Journal of Infection, 2024 - Elsevier
Vaccine-induced immunoglobulin G (IgG) profiles can vary with respect to the predominant
subclasses that characterize the response. Among IgG subclasses, IgG4 is reported to have …
subclasses that characterize the response. Among IgG subclasses, IgG4 is reported to have …
[HTML][HTML] Evaluating the Quality of Studies Assessing COVID-19 Vaccine Neutralizing Antibody Immunogenicity
M Katzmarzyk, R Naughton, I Sitaras, H Jacobsen… - Vaccines, 2024 - mdpi.com
Objective: COVID-19 vaccine-neutralizing antibodies provide early data on potential vaccine
effectiveness, but their usefulness depends on study reliability and reporting quality …
effectiveness, but their usefulness depends on study reliability and reporting quality …
[HTML][HTML] Navigating the Landscape of B Cell Mediated Immunity and Antibody Monitoring in SARS-CoV-2 Vaccine Efficacy: Tools, Strategies and Clinical Trial Insights
S O'Reilly, J Byrne, ER Feeney, PWG Mallon, V Gautier - Vaccines, 2024 - mdpi.com
Correlates of Protection (CoP) are biomarkers above a defined threshold that can replace
clinical outcomes as primary endpoints, predicting vaccine effectiveness to support the …
clinical outcomes as primary endpoints, predicting vaccine effectiveness to support the …
Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 …
TM Babu, X Shen, RS McClelland… - Open Forum …, 2024 - academic.oup.com
We evaluated the immunologic response to a novel vaccine regimen that included 2 doses
of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent …
of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent …